TITLE

The glycemic go-getters

AUTHOR(S)
Chase, James
PUB. DATE
January 2012
SOURCE
Medical Marketing & Media;Jan2012, Vol. 47 Issue 1, p42
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the achievements of Victoza PCP which has posted billions of dollars in global sales for 2011. It highlights the approval of a non-insulin injectable glucagon-like peptide 1 (GLP-1) given by the U.S. Food and Drug Administration (FDA) indicated for patients with Type 2 diabetes in January 2010. Vice president Will Bainbridge confirms the move of the company to reassure the patients using programs like VictozaCare.
ACCESSION #
70125537

 

Related Articles

  • Two new diabetes drugs on the market.  // Cardiology Today;Mar2012, Vol. 15 Issue 3, p35 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of two drugs indicated for the treatment of type 2 diabetes.

  • Colesevelam: A novel drug for comorbid diabetes and dyslipidemia. Dixit, Alok; Pandey, Pinki // Chronicles of Young Scientists;Oct-Dec2012, Vol. 3 Issue 4, p312 

    The article discusses the approval of the colesevelam hydrochloride by the U.S. Food and Drug Administration for type 2 diabetes mellitus and dyslipidemia. It mentions that the drug is approved as adjunctive treatment for T2DM in combination with sulfonylurea, metformin, and insulin therapy. It...

  • FDA actions.  // Neurology Alert;Jul2011 Pharmacology Watch, p2 

    The article reports on the actions taken by the U.S. Food and Drug Administration on several drugs including the approval of linagliptin for type 2 diabetes in adults and rilpivirine for adults with HIV-1 and the eventual pulling out of Rosiglitazone (Avandia) from the U.S. market.

  • Amylin's Bydureon NDA Data Held Back, FDA Says. Winter, Peter // BioWorld Today;6/27/2012, Vol. 23 Issue 124, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) requested Amylin Pharmaceuticals for additional information on the cardiovascular effects of Bydureon, a drug for the treatment of type II diabetes. Amylin issued a statement on FDA's agreement to use the data of Byetta, a...

  • New Drug for Type 2 Diabetes.  // Clarendon Enterprise (TX);2/ 7/2013, Vol. 24 Issue 6, p4 

    The article focuses on the new drug Invokana of canagliflozin, which has an approval recommendation from the U.S. Food and Drug Administration (FDA) in treating adult's type 2 diabetes.

  • FDA OKs 3 Diabetes Drugs.  // Monthly Prescribing Reference;Mar2013, Vol. 29 Issue 3, pA-13 

    The article announces that U.S. Food & Drug Administration has approved three drugs including Nesina (alogliptin), Oseni (alogliptin and pioglitazone), and Kazano (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults.

  • FDA Approves Janumet XR.  // Chain Drug Review;2/27/2012, Vol. 34 Issue 4, p44 

    The article reports that the U.S. Food and Drug Administration has approved Janumet XR tablets for the treatment of type 2 diabetes.

  • FDA approves updated linagliptin label.  // Endocrine Today;Sep2012, Vol. 10 Issue 9, p10 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of a supplemental drug application for linagliptin tablets for use as an add-on therapy to insulin in patients with type 2 diabetes and for use in patients with type 2 diabetes with severe chronic renal impairment.

  • Jardiance OK'd as Type 2 Diabetes Treatment.  // Chain Drug Review;9/29/2014, Vol. 36 Issue 15, p74 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) on the drug Jardiance for the treatment of type 2 diabetes.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics